Guardian Pharmacy Q2 revenue beats estimates; 2026 outlook lifted

Guardian Pharmacy Services

06/08/2026 21:21

Overview
U.S. long-term care pharmacy's Q2 revenue rose 2% yr/yr, beating analyst expectations
Adjusted EPS for Q2 was $0.29; no analyst estimate provided for comparison
Company raised full-year 2026 revenue and adjusted EBITDA guidance

Outlook
Guardian raises 2026 revenue guidance to $1.43 bln-$1.45 bln from $1.40 bln-$1.42 bln
Company lifts 2026 adjusted EBITDA forecast to $129 mln-$131 mln from $122 mln-$127 mln
Company says strong Q2 and outlook for remainder of year prompted guidance increase

Result Drivers
IRA PRICE REDUCTIONS - Co said IRA-related pricing reductions limited reported revenue growth in Q2
OPERATING EFFICIENCY - Co attributed expanded profitability to benefits of scale, purchasing leverage and improved operating efficiency
RESIDENTS SERVED - Residents served grew 8% yr/yr, contributing to business growth

Company press release: ID:nBwbsRnFCa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$351.77 mln
$340.04 mln (5 Analysts)
Q2 Adjusted EPS
 
$0.29
 
Q2 EPS
 
$0.34
 
Q2 Net Income
 
$22.12 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy."
Wall Street's median 12-month price target for Guardian Pharmacy Services, Inc. is $47.00, about 16% above its August 5 closing price of $40.50
The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 30 three months ago

Reuters Recommended Reads
Aug 4 - PACS Group reports Q2 revenue beat on higher occupancy, raises outlook
Aug 5 - Cencora's Q3 revenue slightly beats estimates on Healthcare Solutions growth
Aug 5 - McKesson raises annual profit forecast on strong growth in specialty drug business

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)